Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Declines By 40.3%

Adlai Nortye Ltd. (NASDAQ:ANL) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 4,300 shares, a decline of 40.3% from the February 28th total of 7,200 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 8,000 shares, the days-to-cover ratio is currently 0.5 days.

Adlai Nortye Stock Performance

Shares of ANL stock opened at $1.94 on Friday. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48. The stock’s 50 day simple moving average is $2.20 and its two-hundred day simple moving average is $2.22.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.